Overview

APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study

Status:
Unknown status

Trial end date:
2019-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the APIXABAN use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation in Real-Life Setting in France, data from SNIIRAM (French data base).

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Apixaban
Dabigatran
Rivaroxaban
Vitamin K